Terms ending in 2030
Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,753,464 | Methods and Compositions for Targeting Polyubiquitin In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,865,122 | Methods and Compositions for Protein Labelling In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,591,897 | ANTI-ERBB2 Antibody Adjuvant Therapy In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 9,327,035 | Anti-Her Antibodies In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,710,189 | ANTI-FGFR3 Antibodies and Methods Using Same In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 9,499,623 | ANTI-FGFR3 Antibodies and Methods Using Same In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 10,000,571 | ANTI-FGFR3 Antibodies and Methods Using Same In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 10,287,356 | ANTI-FGFR3 Antibodies and Methods Using Same In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 11,401,333 | ANTI-FGFR3 Antibodies and Methods Using Same In force · High confidence | Genentech, Inc. | In force | High confidence | |
| US 8,158,624 | Purine PI3K Inhibitor Compounds and Methods of Use In force · High confidence | Genentech, Inc. | In force | High confidence | |
| 63 more term ends in 2030 · Pro | |||||
10 of 73 patents shown. Soonest term end first, then patent number.
Pro members see all 73.
58 of these are in force and held by Genentech, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.